Myeloid cells in tumor microenvironment
Myeloid cells in tumor microenvironment Myeloid cells play a crucial role within the tumor microenvironment (TME), significantly influencing cancer progression, immune responses, and therapeutic outcomes. Originating from hematopoietic stem cells in the bone marrow, myeloid cells encompass a diverse array of immune cells, including macrophages, dendritic cells, neutrophils, and myeloid-derived suppressor cells (MDSCs). Their functions within the TME are complex and often dualistic, capable of both promoting and inhibiting tumor growth depending on the context.
In the setting of cancer, myeloid cells are recruited to the tumor site through various chemokines and cytokines released by tumor cells and stromal components. Once within the TME, these cells undergo functional polarization influenced by local signals. For instance, macrophages can differentiate into either classically activated M1 macrophages, which exhibit pro-inflammatory and anti-tumor properties, or alternatively activated M2 macrophages, which tend to promote tumor growth, angiogenesis, and immune suppression. Tumor-associated macrophages (TAMs), predominantly resembling the M2 phenotype, are often abundant in solid tumors and have been linked to worse prognosis due to their role in supporting tumor invasion and metastasis.
Neutrophils, traditionally recognized for their role in acute inflammation and pathogen clearance, are also recruited to tumors where they can exhibit pro-tumorigenic activities. Tumor-associated neutrophils (TANs) can facilitate tumor progression by promoting angiogenesis, remodeling the extracellular matrix, and suppressing adaptive immune responses. Similarly, MDSCs are a heterogeneous group of immature myeloid cells known for their potent immunosuppressive effects. They inhibit T cell activation and proliferation, thus helping tumors evade immune surveillance and resist immunotherapies.
Dendritic cells in the TME often display impaired antigen-presenting functions, which hampers effective anti-tumor immune responses. Tumors can induce the development of tolerogenic dendritic cells that contribute to immune escape. The accumulation of these immunosuppressive myeloid populations creates a hostile environment for cytotoxic T lymphocytes and other effector immune cells, making tumors more resilient against immune-mediated destruction.
Targeting myeloid cells within the TME has emerged as a promising therapeutic strategy. Approaches include inhibiting the recruitment of myeloid cells, reprogramming TAMs from M2 to M1 phenotype, and blocking the immunosuppressive functions of MDSCs. Several clinical trials are underway to evaluate agents that modulate myeloid cell activity, often in combination with other immunotherapies such as checkpoint inhibitors. The goal is to restore immune competence within the TME and improve responses to cancer treatments.
Understanding the dynamic roles of myeloid cells in the tumor microenvironment offers valuable insights into tumor biology and immune evasion mechanisms. As research advances, manipulating these cells holds the potential to transform cancer therapy and achieve more durable remissions.